Literature DB >> 11560866

beta-Oxidation of simvastatin in mouse liver preparations.

T Prueksaritanont1, B Ma, X Fang, R Subramanian, J Yu, J H Lin.   

Abstract

All current 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors [simvastatin (SV), lovastatin (LV), atorvastatin, pravastatin, fluvastatin, and cerivastatin] are believed to undergo an atypical beta-oxidation of the dihydroxy heptanoic or heptanoic acid side chain. Metabolites, which are shortened by two- and/or four-carbon units consistent with beta-oxidation products, have been reported exclusively in rodents following LV and SV administration and across species (rodents, dogs, and humans) following the other statins. In this study, in vitro formation of a beta-oxidation product of simvastatin hydroxy acid (SVA) and its intermediates in mouse livers is described. Incubation of SVA with mouse liver preparations fortified with CoASH and ATP led to formation of SV and two major products (P1 and P2). Based on mass spectrometry (MS), tandem mass spectrometry, and/or NMR spectral characteristics, P1 was an alpha,beta-unsaturated metabolite, formed by dehydration of the D,D-dihydroxy heptanoic acid side chain, whereas P2 was probably the L,D-dihydroxy acid isomer of SVA, formed by stereospecific hydration of P1. When NAD(+) was also included in the incubation mixture, there were two additional metabolites with the MS and/or NMR characteristics consistent with a two-carbon shortened product (P3) and its dehydrated derivative (P4). In a complete incubation system with all cofactors (ATP, CoASH, NAD(+), and NADPH) present, there was an additional product with MS spectra and liquid chromatography retention time identical to the beta-oxidized, unsubstituted pentanoic acid metabolite (P5) detected in rats and mice following simvastatin administration. The involvement of CoASH and NAD(+) and the presence of the four metabolic intermediates suggest that SVA (and presumably the other statins) is a substrate for the beta-oxidation enzyme complex in mice. Additionally, the present finding of CoASH-dependent formation of SV substantiates a mechanism proposed previously for the in vivo lactonization of statin hydroxy acids.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11560866

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

Review 1.  Predicting the oxidative metabolism of statins: an application of the MetaSite algorithm.

Authors:  Giulia Caron; Giuseppe Ermondi; Bernard Testa
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

2.  Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite.

Authors:  Rajesh Narwal; Fatemeh Akhlaghi; Anders Asberg; Monica Hermann; Sara E Rosenbaum
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

3.  A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes.

Authors:  Joachim Bucher; Stephan Riedmaier; Anke Schnabel; Katrin Marcus; Gabriele Vacun; Thomas S Weiss; Wolfgang E Thasler; Andreas K Nüssler; Ulrich M Zanger; Matthias Reuss
Journal:  BMC Syst Biol       Date:  2011-05-06

4.  The role of acid-base imbalance in statin-induced myotoxicity.

Authors:  Dhiaa A Taha; Cornelia H De Moor; David A Barrett; Jong Bong Lee; Raj D Gandhi; Chee Wei Hoo; Pavel Gershkovich
Journal:  Transl Res       Date:  2016-03-29       Impact factor: 7.012

5.  Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?

Authors:  Lee M Tatham; Neill J Liptrott; Steve P Rannard; Andrew Owen
Journal:  Molecules       Date:  2019-07-24       Impact factor: 4.411

Review 6.  Biotransformations utilizing β-oxidation cycle reactions in the synthesis of natural compounds and medicines.

Authors:  Alina Swizdor; Anna Panek; Natalia Milecka-Tronina; Teresa Kołek
Journal:  Int J Mol Sci       Date:  2012-12-05       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.